Journal Scans
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women With Node-Positive, Oestrogen-Receptor-Positive Breast Cancer on Chemotherapy
21-Gene Recurrence Score Predicts Breast Cancer Therapy Response
KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, I-T Yeh, P Ravdin, R Bugarini, FL Baehner, NE Davidson, GW Sledge, EP Winer, C Hudis, JN Ingle, EA Perez, KI Pritchard, L Shepherd, JR Gralow, C Yoshizawa, DC Allred, CK Osborne, DF Hayes, for The Breast Cancer Intergroup of North America
Yes
20100001
2010 Jan 1
Lancet Oncol
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women With Node-Positive, Oestrogen-Receptor-Positive Breast Cancer on Chemotherapy
Lancet Oncol. 2010 Jan 1;11(1):55-65, KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, I-T Yeh, P Ravdin, R Bugarini, FL Baehner, NE Davidson, GW Sledge, EP Winer, C Hudis, JN Ingle, EA Perez, KI Pritchard, L Shepherd, JR Gralow, C Yoshizawa, DC Allred, CK Osborne, DF Hayes, for The Breast Cancer Intergroup of North America
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogenreceptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence. Methods: The phase...
